Analyst Reaffirms Outperform Rating and 6 Price Target for Geron NASDAQ GERN
Wedbush analyst Robert Driscoll has once again expressed confidence in Geron (NASDAQ: GERN), reiterating an Outperform rating and a $6 ...
© 2024 Stocks Today
Tag: GERN
FDA Reservations on Geron Corporations Imetelstat Application for Anemia in LowerRisk MDS Patients
The FDA has expressed reservations regarding Geron Corporation's imetelstat application for anemia in lower-risk MDS patients, specifically questioning the balance ...
FDA Raises Concerns About Gerons Anemia Drug Imetelstat
Geron shares took a hit today as news broke that FDA staff reviewers have raised red flags about the potential ...
Analyst Reaffirms Buy Rating for Geron with 4 Price Target
Needham analyst Gil Blum has once again expressed optimism for Geron (NASDAQ: GERN), reiterating a Buy rating and holding steady ...
Upcoming FDA Advisory Committee Meeting for Imetelstat A Groundbreaking Treatment for Malignant Stem Cells
On January 30, 2024, the U.S. Food and Drug Administration (FDA) has announced an upcoming advisory committee meeting. The meeting ...
Don't Miss It
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions